Folic acid dihydrate | 75708-92-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: Folic acid dihydrate
• 英文别名: (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;dihydrate
• CAS: 75708-92-8
• 化学式: C19H19N7O6.2H2O
• 分子量: 477.4
• InChiKey: ODYNNYOEHBJUQP-LTCKWSDVSA-N

物化性质

• 熔点：
  250°C
• 溶解度：
  酸水溶液（微溶）、碱水溶液（微溶）、DMSO（微溶）
• 稳定性/保质期：
  在指定条件下稳定，远离氧化物，避光。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.69
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  211
• 氢给体数：
  8
• 氢受体数：
  12

安全信息

• TSCA：
  Yes
• WGK Germany：
  3
• RTECS号：
  LP5425000

制备方法与用途

用途：此药物主要用于治疗贫血，并能有效预防多种神经系统疾病。

反应信息

• 作为反应物：
  描述：

  Folic acid dihydrate 在 folate 、 氢氧化钾 、 sodium hydroxide 、 solutions 、 ammonium hydroxide 作用下， 以 水 为溶剂， 生成 folate
  参考文献：
  名称：

  CONTROLLED RELEASE COMPOSITION AND PROCESS

  摘要：

  一种用于封装和控制释放的组合物，包括一个水不溶性基质，该基质包括一个非共价交联的宿主分子，该宿主分子由多价阳离子交联，非聚合物，具有多个羧基官能团，至少部分具有芳香性或杂环芳香性，并且包括至少一个白垩质或5-取代白垩质基团。该组合物还可以包括一个客体分子（例如药物），该客体分子可以被封装在基质内，并随后释放。

  公开号：

  US20100028420A1

文献信息

• Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
  申请人：Yang J. David

  公开号：US20050084448A1

  公开（公告）日：2005-04-21

  The invention provides, in a general sense, a new labeling strategy employing 99m Tc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99m Tc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

  本发明提供了一种新的标记策略，使用乙二胺四乙酸（EC）螯合的99mTc。EC与各种配体结合，并螯合到99mTc上，用作组织特异性疾病的成像剂。本发明的药物结合物也可以用作预后工具或用作将治疗药物传递到哺乳动物体内特定部位的工具。还提供用于组织特异性疾病成像的试剂盒。
• Preparation and purification of citrovorum factor
  申请人：The Government of the United States of America

  公开号：US04148999A1

  公开（公告）日：1979-04-10

  Improved methods for the preparation and purification of citrovorum factor are disclosed. The method includes improved procedures for hydrogenation of 10-formylfolic acid as well as for the reduction of folic acid. Also disclosed are improved procedures for opening of the imidazoline ring, and a non-chromatographic method for the purification of crude samples of citrovorum factor.

  本发明公开了制备和纯化柠檬酸亚甲四氢叶酸的改进方法。该方法包括改进的10-甲酰基叶酸的氢化程序以及叶酸还原程序。此外，还公开了开放咪唑环的改进程序以及粗柠檬酸亚甲四氢叶酸样品的非色谱纯化方法。
• Preparation of tetrahydrofolic acid from folic acid
  申请人：United States of America

  公开号：US04206307A1

  公开（公告）日：1980-06-03

  Improved methods for the preparation and purification of citrovorum factor are disclosed. The method includes improved procedures for hydrogenation of 10-formylfolic acid as well as for the reduction of folic acid. Also disclosed are improved procedures for opening of the imidazoline ring, and a non-chromatographic method for the purification of crude samples of citrovorum factor.

  本发明揭示了制备和纯化柠檬酸亚甲四氢叶酸的改进方法。该方法包括改进的10-甲酰基叶酸的氢化程序，以及叶酸还原的改进程序。此外，本发明还揭示了开放咪唑环的改进程序，以及粗柠檬酸亚甲四氢叶酸样品的非色谱纯化方法。
• Optical imaging probes
  申请人：Poss G. Kirtland

  公开号：US20050214221A1

  公开（公告）日：2005-09-29

  This invention relates to optical imaging probes and the use of such probes for diagnosing and monitoring disease, and disease treatment. The optical imaging probes of the current invention can be used to identify and characterize normal and diseased tissues with regards to altered metabolic activity.

  本发明涉及光学成像探针及其在诊断和监测疾病以及疾病治疗中的应用。本发明的光学成像探针可用于识别和表征在代谢活动方面发生改变的正常和疾病组织。
• Ethylenedicysteine (EC)-Drug Conjugates Compositions and Methods for Tissue Specific Disease Imaging
  申请人：Yang J. David

  公开号：US20070122342A1

  公开（公告）日：2007-05-31

  The invention provides, in a general sense, a new labeling strategy employing 99m Tc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99m Tc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

  本发明提供了一种新的标记策略，采用乙二胺四乙酸（EC）螯合的99mTc。EC与各种配体结合，并螯合到99mTc上，用作组织特异性疾病的成像剂。本发明的药物结合物也可以用作预后工具或用作将治疗剂送到哺乳动物体内特定部位的工具。还提供了用于组织特异性疾病成像的试剂盒。